Renal phosphate loss in long-term kidney transplantation

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 2, 2012, Pages 323-331

  Sirilak, Supinda ^a   Chatsrisak, Kamonwan ^a   Ingsathit, Atiporn ^a   Kantachuvesiri, Surasak ^a   Sumethkul, Vasant ^a   Stitchantrakul, Wasana ^a   Radinahamed, Piyanuch ^a   Disthabanchong, Sinee ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; FIBROBLAST GROWTH FACTOR 23; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PARATHYROID HORMONE; PHOSPHATE;

ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HYPOPHOSPHATEMIA; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE METABOLISM; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; RENAL OSTEODYSTROPHY; RENAL PHOSPHATE LOSS;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPARATHYROIDISM; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARATHYROID HORMONE; PHOSPHATES; THAILAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 84857179148     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06380611     Document Type: Article

References (37)

1. Evenepoel P, Meijers BK, de Jonge H, Naesens M, Bammens B, Claes K, Kuypers D, Vanrenterghem Y: Recovery of hyper-phosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 3: 1829-1836, 2008
2. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates hy-perphosphatemia but accentuates calcitriol deficiencyinchronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
3. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y: FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65: 1943-1946, 2004
4. Claesson K, Hellman P, Frodin L, Rastad J: Prospective study of calcium homeostasis after renal transplantation. World J Surg 22: 635-641, 1998.
5. Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, Juppner H, Wolf M: Post-transplant hypophosphatemia: Tertiary'hyper-phosphatoninism'? Kidney Int 70: 1486-1494, 2006
6. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003
7. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M: Fibro-blast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
8. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
9. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS: Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21: 1187-1196, 2006
10. Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y: Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 5: 1268-1276, 2010
11. Parfitt AM: Misconceptions IV-the hypophosphatemia of primary hyperparathyroidism is the result of renal phosphate wasting. Bone 35: 345-347, 2004
12. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39[2 Suppl 1]: S81-S112, 2002
13. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
14. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2600-2608, 2007
15. Karim Z, Gerard B, Bakouh N, Alili R, Leroy C, Beck L, Silve C, Planelles G, Urena-Torres P, Grandchamp B, Friedlander G, Prie D: NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med 359: 1128-1135, 2008
16. Tataranni T, Biondi G, Cariello M, Mangino M, Colucci G, Rutigliano M, Ditonno P, Schena FP, Gesualdo L, Grandaliano G: Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression. Am J Transplant 11: 1656-1664, 2011
17. Kawarazaki H, Shibagaki Y, Shimizu H, Kawarazaki W, Ito N, Ishikawa A, Fukumoto S, Fujita T: Persistent high level of fibro-blast growth factor 23 as a cause of post-renal transplant hypo-phosphatemia. Clin Exp Nephrol 11: 255-257, 2007
18. Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y: Tertiary'hyperphosphatoninism' accentuates hypo-phosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7: 1193-1200, 2007
19. Kawarazaki H, Shibagaki Y, Fukumoto S, Kido R, Nakajima I, Fuchinoue S, Fujita T, Fukagawa M, Teraoka S: The relativerole of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation:A1-year prospective observational study. Nephrol Dial Transplant 26: 2691-2695, 2011
20. Felsenfeld AJ, Gutman RA, Drezner M, Llach F: Hypo-phosphatemia in long-term renal transplant recipients: Effects on bone histology and 1,25-dihydroxycholecalciferol. Miner Electrolyte Metab 12: 333-341, 1986
21. Cayco AV, Wysolmerski J, Simpson C, Mitnick MA, Gundberg C, Kliger A, Lorber M, Silver D, Basadonna G, Friedman A, Insogna K, Cruz D, Bia M: Posttransplant bone disease: Evidence for a high bone resorption state. Transplantation 70: 1722-1728, 2000
22. Giannini S, D'Angelo A, Carraro G, Antonello A, Di Landro D, Marchini F, Plebani M, Zaninotto M, Rigotti P, Sartori L, Crepaldi G: Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation. Clin Nephrol 56: 353-363, 2001
23. Ewers B, Gasbjerg A, Moelgaard C, Frederiksen AM, Marckmann P: Vitamin D status in kidney transplant patients: Need for intensified routine supplementation. Am J Clin Nutr 87: 431-437, 2008
24. Holick MF, Chen TC: Vitamin D deficiency: A worldwide problem with health consequences. Am J Clin Nutr 87: 1080S-1086S, 2008
25. LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM: Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am J Kidney Dis 45: 1026-1033, 2005
26. Stavroulopoulos A, Cassidy MJ, Porter CJ, Hosking DJ, Roe SD: Vitamin D status in renal transplant recipients. Am J Transplant 7: 2546-2552, 2007
27. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004
28. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T: Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78: 975-980, 2010
29. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117: 4003-4008, 2007
30. Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE: Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195: 125-131, 2007
31. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidityin maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
32. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005
33. Connolly GM, Cunningham R, McNamee PT, Young IS, Maxwell AP: Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation 87: 1040-1044, 2009
34. Larsson TE, Olauson H, Hagstrom E, Ingelsson E, Arnlov J, Lind L, Sundstrom J: Conjoint effects ofserumcalcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol 30: 333-339, 2010
35. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I: Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22: 956-966, 2011
36. Brunelli SM, Goldfarb S: Hypophosphatemia: Clinical consequences and management. J Am Soc Nephrol 18: 1999-2003, 2007
37. Cirillo M, Ciacci C, De Santo NG: Age, renal tubular phosphate reabsorption, and serum phosphate levels in adults. N Engl J Med 359: 864-866, 2008